Evidence map›Paper›PMID 34750607›Full record

ArticleBioscience reports2021

Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach.

Daniele Mercatelli, Francesco Formaggio, Marco Caprini, Andrew Holding, Federico M Giorgi

Open access · goldAbstract read
In one paragraph

Article in Bioscience reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Daniele MercatelliDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Francesco FormaggioDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Marco CapriniDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.
Andrew HoldingYork Biomedical Research Institute, University of York, Heslington, York, YO10 5DD, U.K.ORCID 0000-0002-8459-7048
Federico M GiorgiDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0002-7325-9908
University of Bologna · ITUniversity of York · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCell-surface proteins have been widely used as diagnostic and prognostic markers in cancer research and as targets for the development of anticancer agents. So far, very few attempts have been made to characterize the surfaceome of patients with breast cancer, particularly in relation with the current molecular breast cancer (BRCA) classification. In this view, we developed a new computational method to infer cell-surface protein activities from transcriptomics data, termed 'SURFACER'.

methodsGene expression data from GTEx were used to build a normal breast network model as input to infer differential cell-surface proteins activity in BRCA tissue samples retrieved from TCGA versus normal samples. Data were stratified according to the PAM50 transcriptional subtypes (Luminal A, Luminal B, HER2 and Basal), while unsupervised clustering techniques were applied to define BRCA subtypes according to cell-surface proteins activity.

resultsOur approach led to the identification of 213 PAM50 subtypes-specific deregulated surface genes and the definition of five BRCA subtypes, whose prognostic value was assessed by survival analysis, identifying a cell-surface activity configuration at increased risk. The value of the SURFACER method in BRCA genotyping was tested by evaluating the performance of 11 different machine learning classification algorithms.

conclusionsBRCA patients can be stratified into five surface activity-specific groups having the potential to identify subtype-specific actionable targets to design tailored targeted therapies or for diagnostic purposes. SURFACER-defined subtypes show also a prognostic value, identifying surface-activity profiles at higher risk.

Indexed as

Gene Expression ProfilingMachine LearningTranscriptomeBiomarkers, TumorBreast NeoplasmsCase-Control StudiesDatabases, GeneticFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansPredictive Value of TestsPrognosisProtein Interaction MapsSignal TransductionBiomarkers, Tumorbioinformaticsbiomarkersbreast cancermaster regulatorssurfaceometranscriptomics

Identifiers

PMID34750607
PMCPMC8655506
OpenAlexW3213585453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.